Naming specialist NOMEN International launches healthcare division
NOMEN Healthcare – You care. We care. Brandcare®
Because 50 to 70% of names submitted to the European Medicines Agency (EMA) are rejected, NOMEN decided to lend a helping hand.
With over 30 years experience of developing names for products, global brands and listed companies in sectors as varied as the automotive industry (naming the Clio as the first project) and fragrances, smart technology processors, OTC and prescription drugs, it seemed the pharmaceutical sector required the special attention of a dedicated team versed in understanding its stringent regulatory requirements and specificities.
NOMEN Healthcare is run out of our office in Düsseldorf, Germany and supports NOMEN International in the creation and development of brand and corporate names in the pharmaceutical and biotech industries.
From the early stages of the creative naming brief NOMEN Healthcare draws from the client’s project description, the regulatory requirements are factored in to ensure that names are developed with the best chance of receiving approval from the regulatory bodies such as the Food and Drug Administration (FDA), the Medicines and Healthcare products Regulatory Agency (MHRA) and the EMA.
NOMEN’s Brandcare approach includes intense checks once a short-list of names or straplines is created: association tests, linguistic & cultural tests, regulatory screenings including simulation studies with expert panels of doctors and pharmacists, market research and WebCheck of brand digital potential.
NOMEN Healthcare starts with a strong expertise, having created brand names such as Revaxis® for Sanofi Pasteur to protect adults from diphtheria, tetanus and polio and Ameluz® for Biofrontera, used in photodynamic therapy (PDT) of actinic keratosis.